Samsung Biologics Granted Terra Carta Seal
Award given in recognition of CDMO’s commitment to promoting sustainable future
Coming off its EcoVadis “gold” rating this past October, Samsung Biologics, a contract development and manufacturing organization (CDMO), has been awarded the Sustainable Markets Initiative’s Terra Carta Seal. The Seal was launched at COP26 (the 2021 United Nations Climate Change Conference) by His Majesty King Charles III when he was Prince of Wales, and it recognizes global companies that are putting innovation at the forefront and demonstrating their commitment to establishing sustainable markets. It is awarded to companies whose ambitions are aligned with those of the Terra Carta, a recovery plan for nature, people, and planet, that was launched in January 2021.
Samsung is one of the 19 companies to have been awarded the 2022 Terra Carta Seal. The company affirmed its commitment to achieving net zero greenhouse gas emissions across its direct operations and supply chain by 2050 or earlier, as part of its global response to climate change.
“We are honored to be recognized with the Terra Carta Seal by the Sustainable Markets Initiative for Samsung Biologics’ contribution in working alongside our industry peers for this global effort,” says John Rim, CEO and president of Samsung Biologics. “Healthcare is at a pivotal moment, and through our collaborative efforts, we can contribute to shaping climate-resilient practices to influence and help shape policy across the pharmaceutical and healthcare sectors.”
Read more about the CDMO’s award here.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
